3 ms·
What you quoted is the shortend version of the goals of the funding program, here is a more complete description: https://www.bmbf.de/foerderungen/bekanntmachun
by bildung 6y ago
What you quoted is the shortend version of the goals of the funding program, here is a more complete description: https://www.bmbf.de/foerderungen/bekanntmachung-3035.html https://www.bmbf.de/foerderungen/bekanntmachung-3035.html
The program is funding clinical trials 1 to 3, having bigger cohorts for trials 2 and 3, and scaling up production while trials are still in progress. In short: Everything that makes vaccine development expensive. Finding the actual vaccine candidates is the cheap part.
- adriancr 6y ago> Finding the actual vaccine candidates is the cheap part. Do you have any sources on that?
- bildung 6y agoSee here: https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(18)30346-2/fulltext https://www.thelancet.com/journals/langlo/article/PIIS2214-1... Going from zero to preclinical is about 1/3 of the costs of going from preclinical to phase 2. Phase 3 is not part of this study, neither is parallel production.
- adriancr 6y agoThat is a study of existing vaccines based on existing practices (which result in astrazeneca's 70% effective vaccine) BioNTech is a different vaccine type, hence effectiveness and fact that both moderna and pfizer license it. The fact that Germany subsidised the last stages to speed it up doesnt mean technology should be public access. That's for the government and company to negotiate.